CRDL Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of --. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Cardiol Therapeutics, Inc. has a consensus price target of $7.76, signalling upside risk potential of 681.7%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 663.89%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Edesa Biotech, Inc., analysts believe Cardiol Therapeutics, Inc. is more attractive than Edesa Biotech, Inc..

Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Cardiol Therapeutics, Inc.'s net income of -$7.2M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience Corp. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of -2178.51%. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Lexaria Bioscience Corp.'s return on equity of -147.19%.

Cardiol Therapeutics, Inc. has a consensus price target of $7.76, signalling upside risk potential of 681.7%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $4.50 which suggests that it could grow by 747.62%. Given that Lexaria Bioscience Corp. has higher upside potential than Cardiol Therapeutics, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Cardiol Therapeutics, Inc..

Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.221%.

Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.

Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Lexaria Bioscience Corp. quarterly revenues of $174K. Cardiol Therapeutics, Inc.'s net income of -$7.2M is lower than Lexaria Bioscience Corp.'s net income of -$2.7M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus 13.54x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of --. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Cardiol Therapeutics, Inc. has a consensus price target of $7.76, signalling upside risk potential of 681.7%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 483.09%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Cardiol Therapeutics, Inc. is more attractive than Oncolytics Biotech, Inc..

Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Cardiol Therapeutics, Inc.'s net income of -$7.2M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -- compared to Cardiol Therapeutics, Inc.'s net margin of -867.29%. Cardiol Therapeutics, Inc.'s return on equity of -236.38% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Cardiol Therapeutics, Inc. has a consensus price target of $7.76, signalling upside risk potential of 681.7%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 23.56%. Given that Cardiol Therapeutics, Inc. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Cardiol Therapeutics, Inc. is more attractive than Xenon Pharmaceuticals, Inc..

Cardiol Therapeutics, Inc. has a beta of 1.126, which suggesting that the stock is 12.56% more volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

Cardiol Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiol Therapeutics, Inc. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cardiol Therapeutics, Inc. quarterly revenues are --, which are smaller than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Cardiol Therapeutics, Inc.'s net income of -$7.2M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Cardiol Therapeutics, Inc.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiol Therapeutics, Inc. is -- versus 471.23x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.